NHS Dudley Health Economy Medicines Formulary
Home > 8 Malignant disease and immunosuppression > 8.1 Cytotoxic drugs > 8.1.5 Other antineoplastic drugs > Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) - NICE TAG TA453

Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) - NICE TAG TA453

NICE is unable to make a recommendation about the use in the NHS of daratumumab, with lenalidomide and dexamethasone, for treating relapsed or refractory multiple myeloma because no evidence submission was received from Janssen-Cilag. We will review this decision if the company decides to make a submission.

https://www.nice.org.uk/guidance/ta454

Site by Devopa
© Copyright 2019 NHS. All rights reserved.